▲ 0.53%
prev close
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Congressional Trades
20
All tracked trades
Members Trading
13
Unique members
Net Activity
-8
6 buys · 14 sells
Members Who Traded This Stock
20 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-12-19 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 191d ago | — | |
| 2025-12-18 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 188d ago | — | |
| 2025-11-13 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 223d ago | — | |
| 2025-11-12 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 219d ago | — | |
| 2025-05-12 | BMYBristol-Myers Squibb Co. | Sell | $15,001 - $50,000 | 395d ago | — | |
| 2025-04-28 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 190d ago | — | |
| 2025-04-15 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 433d ago | — | |
| 2025-04-01 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 434d ago | — | |
| 2025-03-27 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 470d ago | — | |
| 2025-01-15 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 525d ago | — | |
| 2024-10-29 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 313d ago | — | |
| 2024-01-18 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 688d ago | — | |
| 2023-09-26 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 986d ago | — | |
| 2023-03-07 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1192d ago | — | |
| 2022-03-16 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1555d ago | — | |
| 2021-11-10 | BMYBristol-Myers Squibb Co. | Sell | $15,001 - $50,000 | 1419d ago | — | |
| 2021-06-07 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1311d ago | — | |
| 2020-07-10 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1311d ago | — | |
| 2019-04-08 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1311d ago | — | |
| 2018-04-17 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 1311d ago | — |
2025-12-19
Gilbert Cisneros
BMY
Amount
$1,001 - $15,000
Filed
191d ago
2025-12-18
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
188d ago
2025-11-13
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
223d ago
2025-11-12
Gilbert Cisneros
BMY
Amount
$1,001 - $15,000
Filed
219d ago
2025-05-12
Jefferson Shreve
BMY
Amount
$15,001 - $50,000
Filed
395d ago
2025-04-28
Julia Letlow
BMY
Amount
$1,001 - $15,000
Filed
190d ago
2025-04-15
Tommy Tuberville
BMY
Amount
$1,001 - $15,000
Filed
433d ago
2025-04-01
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
434d ago
2025-03-27
Greg Landsman
BMY
Amount
$1,001 - $15,000
Filed
470d ago
2025-01-15
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
525d ago
2024-10-29
Valerie Hoyle
BMY
Amount
$1,001 - $15,000
Filed
313d ago
2024-01-18
John James
BMY
Amount
$1,001 - $15,000
Filed
688d ago
2023-09-26
Greg Stanton
BMY
Amount
$1,001 - $15,000
Filed
986d ago
2023-03-07
Daniel Goldman
BMY
Amount
$1,001 - $15,000
Filed
1192d ago
2022-03-16
John Rutherford
BMY
Amount
$1,001 - $15,000
Filed
1555d ago
2021-11-10
Carol Devine Miller
BMY
Amount
$15,001 - $50,000
Filed
1419d ago
2021-06-07
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1311d ago
2020-07-10
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1311d ago
2019-04-08
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1311d ago
2018-04-17
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1311d ago
Recent News
Powered by Polygon.io
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Prediction: U.S. Value Stocks Will Outperform for 10 Years. Which ETFs Should You Buy?
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-12-19 · Purchase
$1,001 - $15,000
Julie Johnson
2025-12-18 · Sale
$1,001 - $15,000
Julie Johnson
2025-11-13 · Sale
$1,001 - $15,000
Gilbert Cisneros
2025-11-12 · Purchase
$1,001 - $15,000
Jefferson Shreve
2025-05-12 · Sale
$15,001 - $50,000
Julia Letlow
2025-04-28 · Sale
$1,001 - $15,000
Tommy Tuberville
2025-04-15 · Sale
$1,001 - $15,000
Julie Johnson
2025-04-01 · Sale
$1,001 - $15,000
Greg Landsman
2025-03-27 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
John James
2024-01-18 · Sale
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-03-07 · Sale
$1,001 - $15,000
John Rutherford
2022-03-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000
Thomas Suozzi
2021-06-07 · Sale
$1,001 - $15,000
Thomas Suozzi
2020-07-10 · Sale
$1,001 - $15,000
Thomas Suozzi
2019-04-08 · Sale
$1,001 - $15,000
Thomas Suozzi
2018-04-17 · Purchase
$1,001 - $15,000